Study of Nicotinamide Riboside Effects on Vascular Aging in Young Adults With and Without Adverse Childhood Experiences

What this Trial Is About

Researchers are investigating how adverse childhood experiences ACEs affect the health of blood vessels and increase the risk of future heart disease in young adults. The study focuses on a protein called SIRT1, which helps keep blood vessels healthy, and how its activity is reduced in people with four or more ACEs. By understanding these changes, the study aims to find ways to improve blood vessel function in those affected by early life stress. Participants will take part in a randomized, controlled trial where some will receive a dietary supplement called nicotinamide riboside NR for four weeks, taken twice daily at a total dose of 2,000 mg per day. This supplement is being studied for its ability to increase SIRT1 activity by boosting cellular NAD levels, potentially improving blood vessel function. Others will receive a placebo with no active ingredient. The study compares young adults with high ACE exposure to those without ACEs, using both cross-sectional and intervention phases. Throughout the study, participants will undergo various tests to measure blood vessel function, SIRT1 levels and activity, inflammation, and oxidative stress before and after the supplementation period. They will complete daily logs to track supplement use, and the research team will monitor changes in vascular health indicators over the four weeks. The total participation period includes baseline assessments, the 4-week supplementation, and follow-up measurements to evaluate the effects of the intervention.

ACEs, SIRT1, and Premature Vascular Aging in Humans